By vgreene, 15 April, 2020 Study considerations: small sample size; most pts received at least 1 other antiviral; excl pts w/ serious comorbidities; virologic (not clinical) outcomes measured
By vgreene, 15 April, 2020 1 HCQ-treated pt developed severe dz and D/C tx; 4 ADRs reported in HCQ group vs 3 in control group
By vgreene, 15 April, 2020 86.7% of HCQ group vs 93.3% of control group had negative viral PCR at day 7; median time to virologic clearance was 4 days in HCQ group vs 2 days in control group; median time to defervescence was 1 day in both groups; radiological progression on CT seen
By vgreene, 15 April, 2020 RCT: 30 hospitalized pts w/ confirmed COVID-19 randomized to HCQ 400 mg daily x5 days or placebo; other antivirals incl nebulized IFN (100%), umifenovir (73%), LPV/r (7%); excl pts w/ serious comorbidities or organ dysfunction
By vgreene, 15 April, 2020 No Evidence of Clinical Efficacy of Hydroxychloroquine in Patients Hospitalized for COVID-19 Infection and Requiring Oxygen: Results of a Study Using Routinely Collected Data to Emulate a Target Trial
By vgreene, 15 April, 2020 Study considerations: not peer reviewed; non-randomized; weighted propensity score model; only incl pts w/ mild dz; different protocols at study sites; possible selection bias
By vgreene, 15 April, 2020 No difference in primary outcome (ICU transfer or death by day 7): 21% in HCQ vs 22% in no-HCQ; similar rates of death (HCQ 3%, no-HCQ 5%) and progression to ARDS (HCQ 28%, no-HCQ 24%); 8 HCQ pts had ECG changes requiring D/C, 1 pt had heart block
By vgreene, 15 April, 2020 7-day median time btwn sx and admission; HCQ group had lower rates of comorbidities and received add'l abx incl AZ (20%); no-HCQ group had higher rates of confusion at admission; 8 pts in no-HCQ group received HCQ >48h after admission